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(E.N. da Silva).Twenty-three naphthoimidazoles and six naphthoxazoles were synthesised and evaluated against sus-
ceptible and rifampicin- and isoniazid-resistant strains ofMycobacterium tuberculosis. Among all the com-
pounds evaluated, fourteen presented MIC values in the range of 0.78 to 6.25 lg/mL against susceptible
and resistant strains of M. tuberculosis. Five structures were solved by X-ray crystallographic analysis.
These substances are promising antimycobacterial prototypes.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Tuberculosis (TB) is one of the most widespread diseases in the
world, responsible for approximately 1.3 million deaths annually.1
Although the currently available clinical treatments can cure most
cases of TB with drug susceptible, problems such as the long dura-
tion of treatment, the need for multiple drug therapy, antimicro-
bial resistance, and co-infection with HIV necessitate the
discovery of new drugs to treat TB.2 Furthermore, the complex
pathobiology ofM. tuberculosis, which enables the organism to per-
sist in a dormant stage for years, makes treatment even more
difﬁcult.3
It is important to develop new drug prototypes that are both
more active and more effective and that have alternative mecha-ll rights reserved.
5; fax: +55 53 32338863
700 (E.N.d.S.).
a Silva), eufranio@ufmg.brnisms of action against resistant and susceptible bacterial strains.
Although a large number of molecules have been developed as po-
tential new drugs, none have emerged for clinical use in the last
45 years.4,5 However, there are a wide variety of research resources
and strategies aimed at developing new drugs for TB treatment,
some of which involve the screening of prototypes of synthetic
molecules and natural products.2,6 Biodiversity is an important fac-
tor in the discovery of active substances, leading to further studies
of chemical structural modiﬁcation to enhance their biological
activity.
Recently, several imidazole and oxazole compounds (Fig. 1)
were described as having antimycobacterial activity, and novel
substances were designed based on this important nitrogenated
class of heterocycles.7
Quinones represent a wide and diverse family of plant metabo-
lites.8 In addition to their anti-inﬂammatory and cytotoxic proper-
ties, the activity of quinones against viruses and pathogenic
microorganisms has been reported.9 The main deleterious action
of quinones in biological systems is oxidative stress promotion, a
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Figure 1. Synthetic drugs already tested against Mycobacterium tuberculosis.7
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cellular components.10 One consequence of this mechanism is
the destruction of biological membranes, resulting from peroxida-
tion of the lipid components. Moreover, quinones can interfere
with a variety of biosynthetic pathways, including the destruction
of proteins, damage to the structures of nucleic acids and DNA
strand breaks.11
Our research group has described the synthesis and antimyco-
bacterial activity of naphthoquinoidal and heterocyclic derivatives
from lapachol.12 This quinone is an important natural compound
isolated from the hard core of trees of the bignoniaceous family,
found mainly in the tropical areas of the Western Hemisphere.13
Initially, phenazines from lapachones were obtained, and the com-
pound derived from allyl-b-lapachone was identiﬁed as a potent
substance (Fig. 2) with MIC values equal to 0.78 lg/mL against
pan-susceptible and rifampicin-resistant strains of M. tuberculo-
sis.12 More recently, we reported a phenazine obtained from a lapa-
chol derivative that was considered highly active (MIC 63 lg/mL)
against M. tuberculosis H37Rv, a pan-susceptible strain. Against
ATCC 35822 strains, this compound was less active, with an MIC
value of 12.5 mg/mL.14 Nor-lapachol also presented an
MIC = 3.12 lg/mL against a rifampicin-resistant strain (Fig. 2).14
Imidazole compounds are important drug prototypes for TB.15
Different synthetic strategies have been used to obtain imidazoles
with diverse patterns of substitution, and these substances present
low MIC values, proving the importance of imidazole moieties for
activity against M. tuberculosis.7,15
In the last few years, a series of manuscripts showed that the
functionalisation of thequinoidalmoieties of lapachol and b-lapach-
one into naphthoimidazoles and naphthoxazoles is an important
strategy in the development of new, active compounds.16
In this context, we synthesised naphthoimidazoles and naphth-
oxazoles that were evaluated against pan-susceptibleM. tuberculo-
sis strains that were resistant to isoniazid and rifampicin. Our
strategy was to examine imidazoles and oxazoles with electron-
donating and electron-withdrawing aryl substituents or that hadO
N
N
Phenazine from Allyl-β-lapachone
MIC = 0.78 µg/mL for H37Rv and RIFr
N
O
Phenazine from a
MIC ≤ 3 µg/
Figure 2. Lapachol derivatheterocyclic substitutions, such as quinolinic, isoquinolinic or
pyridinic core structures.
2. Results and discussion
2.1. Chemistry
All of the naphthoimidazoles (Fig. 3) and naphthoxazoles
(Fig. 4) were obtained by the reaction of a quinonoid compound
(b-lapachone) with aromatic aldehydes in the presence of ammo-
nium acetate, as previously described.16,17 In summary, the sub-
stances were separated by column chromatography using eluents
of varying polarity: oxazoles with 94:6 hexane:ethyl acetate and
imidazoles with 90:10 hexane:ethyl acetate.
Some aryl-substituted imidazoles were also obtained from nor-
b-lapachone by the method described in Scheme 1. Nor-lapachol
was obtained from lapachol by the Hooker oxidation method18
and was then reacted with H2SO4 to obtain the cyclised product,
nor-b-lapachone. The unpublished 1,3-azoles (Scheme 1) were ob-
tained through the reaction of nor-b-lapachone, different substi-
tuted aldehydes and a nitrogenating reagent (AcONH4) in acetic
acid. The reaction conditions allowed us to obtain a mixture of
products (imidazoles and oxazoles). In some cases both com-
pounds were obtained, while in other cases, only the imidazole
or oxazole was obtained.
Compound 30was obtained from C-allyl lawsone (29), as previ-
ously described19 and was used to prepare the respective oxazole
derivative 31, described herein for the ﬁrst time (See Scheme 2).
Compounds 1–21were synthesised as previously described,16,17
and substances 22–28 and 31, described for the ﬁrst time, were
isolated and characterised by 1H and 13C NMR, infrared, and elec-
tron-impact mass spectrometry. For some of the compounds, 13C
NMR spectra could not be collected due to their low solubility in
most of the organic solvents tested. For compounds 1, 26, 27, 28
and 31, suitable crystals were obtained, and the structures were
re-conﬁrmed by X-ray crystallographic study.NH
 reduced lapachol
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Figure 3. Naphthoimidazoles 1–21 obtained from b-lapachone.
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Figure 4. Naphthoxazoles 22–24 obtained from b-lapachone.
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Hydrogen atoms bound to carbon and nitrogen were located at
their idealised positions using appropriate HFIX instructions in
SHELXL (43 for the aromatic and 33 for the terminal –CH3 methyl
groups) and were included in subsequent reﬁnement cycles in
the riding-motion approximation with isotropic thermal displace-
ments parameters (Uiso) ﬁxed, respectively, at 1.2 or 1.5 times theO
O
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Scheme 2. Naphthoxazole 31 oUeq of the carbon or nitrogen atom to which they are attached. The
ﬁnal difference Fourier map synthesis showed the highest peak
and deepest hole between (0.480 eÅ3) and (0.427 eÅ3), respec-
tively, for all compounds. The ORTEP-3 program for Windows20
was used for graphic presentations, and the material for publica-
tion was prepared using WinGX-Routine.21 Figure 5 shows the
ORTEP-3 diagrams for ﬁve of the structures.2.3. Biological assays
The minimum inhibitory concentrations (MIC) for all of the
compounds were evaluated against M. tuberculosis H37Rv (pan-
susceptible), rifampicin-resistant (RIFr, ATCC 35338) and isonia-
zid-resistant (INHr, ATCC 35822) strains (Table 1). Eighteen
compounds, 1–3, 5–7, 10, 12–16, 18, 20 and 22–24, displayed MIC
values between 0.78 and 100 lg/mL against all strains. The sub-
stances 25–31 were considered mildly active or inactive with MIC
P100 lg/mL for all three strains.O
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Figure 5. An ORTEP-3 projection of molecules 1, 26, 27, 28 and 31, showing the atom-numbering and displacement ellipsoids at the 50% probability level.
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enhanced its microbicidal activity and is an important prototype for
novel compounds against TB. For example, ortho-substituted
compounds 2 (o-Br, MIC values of 7.6 lM for H37RV and 15.3 lM
for ATCC 35338 and ATCC 35822 strains) and 10 (o-NO2, MIC values
of 267.8, 33.5 and 16.7 lM against the H37Rv, RIFr and INHr strains,
respectively) were more potent than the naphthoimidazole 1 (no
substituent on the phenyl ring, MIC >304.5 lM for all strains). Com-
pound15 (o-CF3,MICvalues = 4.0, 2.0 and4.0 lMagainstH37Rv, RIFr
and INHr strains, respectively) was more active than 1 and its pre-
cursor, b-lapachone (MIC = 6.43 lM for H37RV and ATCC 35338)
indicating that the insertion of –CF3 group at the ortho-position in
the phenyl ring enhances the activity. Substances 13 (o-OMe) and
14 (o-CH3), which were substituted with electron donating groups,
were highly active with MIC values in the range of 4.5–17.4 lM.
Among the meta-substituted phenyl derivatives, those more
active against the M. tuberculosis were m-Br (3), m-F (5) andm-CF3 (16), with MICs below 18.0 lM. The m-CN (8) and m-NO2
(11) compounds were inactive. Substances 3 (m-Br, MIC = 15.3 lM)
and 16 (m-CF3, MIC = 4.0 lM) were the most active imidazoles in
this series for all of the M. tuberculosis strains. Regarding the pres-
ence of substituents at the para position, the naphthoimidazole 12
(p-NO2, MIC = 4.2 lM) was the most active against INHr but was
inactive against the RIFr strain. The p-Br (4), p-CN (9) and p-CF3
(17) compounds were inactive, demonstrating that the insertion
of substituents in this position decreases the activity. Although
compounds 1–17 possess substituents with different sizes, sterics
and electronic properties, no consistent structure–activity relation-
ships could be established.
The naphthoimidazoles 8 and 9 and the naphthoxazoles 22–24
with a cyano group showed diverse activity for all of the M. tuber-
culosis strains; the naphthoimidazoles were inactive, while the
naphthoxazoles exhibited the opposite effect. For the heterocyclic
compounds 18–21, substance 20 with a quinoline group was the
Table 1
MIC (minimum inhibitory concentration) of the tested compounds against Mycobac-
terium tuberculosis H37Rv, rifampicin-resistant M. tuberculosis (RIFr) and isoniazid-
resistant M. tuberculosis (INHr)
Compd No. CMI lg/mL (lM)
H37Rv (ATCC27294) RIFr (ATCC 35338) INHr (ATCC 35822)
1 >100 (>304.5) >100 (>304.5) 12.5 (38.0)
2 3.12 (7.6) 6.25 (15.3) 6.25 (15.3)
3 6.25 (15.3) 6.25 (15.3) 6.25 (15.3)
4 Na Na Na
5 3.12 (9.0) 6.25 (18.0) 6.25 (18.0)
6 25 (72.2) 6.25 (18.0) 6.25 (18.0)
7 12.5 (34.4) 6.25 (17.2) 6.25 (17.2)
8 Na Na Na
9 Na Na Na
10 100 (267.8) 12.5 (33.5) 6.25 (16.7)
11 Na Na Na
12 100 (267.8) Na 1.56 (4.2)
13 6.25 (17.4) 6.25 (17.4) 6.25 (17.4)
14 3.12 (9.0) 1.56 (4.5) 1.56 (4.5)
15 1.56 (4.0) 0.78 (2.0) 1.56 (4.0)
16 1.56 (4.0) 1.56 (4.0) 1.56 (4.0)
17 Na Na Na
18 25 (75.9) 6.25 (19.0) 6.25 (19.0)
19 Na Na Na
20 6.25 (16.4) 60.78 (62.0) 60.78 (62.0)
21 Na Na Na
22 12.5 (35.2) 6.25 (17.6) 6.25 (17.6)
23 12.5 (35.2) 6.25 (17.6) 6.25 (17.6)
24 6.25 (17.6) 1.56 (4.4) 3.12 (8.8)
25 >100 (>318.0) 100 (318.0) >100 (>318.0)
26 >100 (>304.5) 100 (304.5) >100 (>304.5)
27 >100 (>277.5) Nd >100 (>277.5)
28 >100 (>303.6) Nd >100 (>303.6)
29 100 (466.8) 25 (116.7) 100 (466.8)
30 3.12 (14.5) Na Na
31 >100 (>288.7) 100 (288.7) >100 (>288.7)
Rifampicin 60.125 (60.1) >4 (>4.8) 60.125 (60.1)
Isoniazid 60.06 (60.4) 60.06 (60.4) 1 (7.3)
6486 K. C. G. Moura et al. / Bioorg. Med. Chem. 20 (2012) 6482–6488most active, with an MIC 62.0 lM for rifampicin- and isoniazid-
resistant M. tuberculosis.
We have previously described a strategy to modify the C-ring of
the b-lapachone (pyran ring versus furan ring) that was success-
fully used to obtain trypanocidal compounds.22 Substances 25–28
and 31, which have a dihydrofuran ring, were synthesised and
evaluated against all of the M. tuberculosis strains to determine
the effectiveness of this approach against TB. None of these sub-
stances with the dihydrofuran ring were active against M.
tuberculosis.
For compounds 1–11, 20 and 25, the toxicity to human periph-
eral blood mononuclear cells (PBMC) after 72 h of drug exposure
was evaluated by the Alamar Blue assay. For these substances,
the IC50 values were higher than 25.0 lg/mL. The described azoles
represent an important series of compounds with potent activity
against TB with low cytotoxicity.
3. Conclusions
To discover antimicrobial compounds, we describe fourteen
substances with MIC values in the range of 0.78 to 6.25 lg/mL
against strains of M. tuberculosis. Substance 20, with a quinoline
group, was the most active, with an MIC value 60.78 lg/mL for rif-
ampicin-resistant M. tuberculosis (RIFr) and isoniazid-resistant M.
tuberculosis (INHr) strains. Therefore, this substance emerges as
an important derivative for the design of novel active compounds.
The research described here is an important contribution in the
ﬁeld of biologically active heterocyclic compounds against TB, a
neglected disease and an epidemic in many developing countries.4. Experimental protocols
4.1. General procedures
Melting points were determined in a capillary Thomas Hoover
apparatus (Thomas Co., Philadelphia, PA, USA) and are uncorrected.
Analytical grade solvents were used. Column chromatography was
performed on silica gel (Acros Organics 0.035–0.070 mm, pore diam-
eter ca 6 nm). Infrared spectrawere recordedonaPerkin–Elmer FT-IR
spectrometer (Perkin–Elmer Inc., Wellesley, MA, USA). 1H and 13C
NMR spectra were recorded at room temperature using a VNMR-
SYS-500, VarianMR 400 instrument and Gemini 200-MHz spectrom-
eter (Varian, Palo Alto, CA, USA) in the solvents indicatedwith TMS as
an internal reference. Chemical shifts (d) are given in ppm, and
coupling constants (J) are reported in Hertz. The mass spectra were
obtained at 70 eV in a VG Autospec apparatus. The fragments are
describedas a relationshipbetweenatomicmassunits and the charge
(m/z) and the relative abundance in percentage. All the compounds
were nominated using the program ChemBioDraw Ultra 12.0.
4.2. General procedure for the preparation of the imidazoles
and oxazoles
To a solution of b-lapachone (1.1 mmol) in acetic acid (6 mL),
the desired aldehyde (2.5 mmol) was added, and the mixture was
heated to 70 C; at this point, ammonium acetate (16.5 mmol)
was slowly added, and reﬂux was maintained for a determined
time. All the reactions were monitored by thin layer chromatogra-
phy. At the end of the reaction, after addition into water, the pre-
cipitate was puriﬁed by column chromatography using as eluent
a mixture of hexane/ethyl acetate, with a gradient of increasing
polarity, as previously described.16
4.3. 2-(6,6-Dimethyl-5,6-dihydro-4H-benzo[7,8]chromeno[6,5-
d]oxazol-2-yl)benzonitrile (22)
Using 2-formylbenzonitrile (327.5 mg, 2.5 mmol), 22 was
obtained as a yellow solid (53.1 mg, 0.15 mmol, 15% yield, mp
181–183 C).
IR mmax(cm1, KBr): 3061 (Ar-CH), 2225 (C„N), 1599 (C@N),
1237 (C–O–C), 1119 (C–O–C). 1H NMR (200 MHz, DMSO-d6) d:
8.46–8.28 (2H, m), 8.20 (1H, d, J = 8.2 Hz), 8.02 (1H, d, J = 7.4 Hz),
7.88 (1H, t, J = 7.4 Hz), 7.76–7.62 (2H, m), 7.56 (1H, d, J = 8.2 Hz),
3.05 (2H, t, J = 6.4 Hz), 1.98 (2H, t, J = 6.4 Hz), 1.44 (s, 6H). 13C
NMR (50 MHz, DMSO-d6) d: 157.9, 148.0, 135.0, 134.0, 133.3,
130.7, 128.7, 128.5, 127.0, 124.8, 124.5, 123.4, 122.6, 122.2,
121.1, 117.4, 108.7, 101.8, 75.6, 30.6, 26.2, 16.6. MS (70 eV, m/z)
(%): [M+1] 355 (8), 354 (38), 299 (24), 298 (100), 162 (5), 130
(43), 115 (6), 114 (7), 102 (15), 41 (4).
4.4. 3-(6,6-Dimethyl-5,6-dihydro-4H-benzo[7,8]chromeno[6,5-
d]oxazol-2-yl)benzonitrile (23)
Using 3-formylbenzonitrile (327.5 mg, 2.5 mmol), 23 was ob-
tained as a yellow solid (35.0 mg, 0.1 mmol, 10% yield, mp 217–
220 C).
IR mmax(cm1, KBr): 3076 (Ar-CH), 2225 (C„N), 1601 (C@N),
1237 (C–O–C), 1118 (C–O–C). 1H NMR (400 MHz, CDCl3) d: 8.52–
8.43 (2H, m), 8.32–8.30 (1H, m), 7.85 (1H, dd, J = 0.7, 7.8 Hz),
7.73 (1H, td, J = 1.1, 7.8 Hz), 7.64 (1H, td, J = 1.1, 7.8 Hz), 7.53 (2H,
ddd, J = 1.1, 7.8, 15.2 Hz), 3.16 (2H, t, J = 6.6 Hz), 2.00 (2H, t,
J = 6.6 Hz), 1.50 (6H, s). 13C NMR (50 MHz, DMSO-d6) d: 157.9,
148.4, 147.0, 132.9, 130.3, 129.8, 129.5, 129.0, 127.0, 125.2,
124.7, 124.0, 122.6, 121.5, 118.1, 113.1, 101.4, 75.3, 31.5, 26.6,
17.20. MS (70 eV, m/z) (%): [M+1] 355 (10), 354 (38), 299 (26),
298 (100), 162 (8), 130 (50), 115 (7), 114 (7), 102 (18), 41 (4).
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d]oxazol-2-yl)benzonitrile (24)
Using 4-formylbenzonitrile (327.5 mg, 2.5 mmol), 24 was
obtained as a yellow solid (71.0 mg, 0.2 mmol, 20% yield, mp
230–234 C).
IR mmax(cm1, KBr): 3046 (Ar-CH), 2226 (C„N), 1606 (C@N),
1203 (C–O–C), 1120 (C–O–C). 1H NMR (200 MHz, DMSO-d6) d:
8.40–7.80 (8H, m), 3.12 (2H, t, J = 6.7 Hz), 2.02 (2H, t, J = 6.7 Hz),
1.52 (6H, s). 13C NMR (50 MHz, DMSO-d6) d: 158.0, 148.5, 147.0,
138.5, 132.7, 132.4, 131.5, 129.7, 126.9, 126.7, 118.3, 117.5,
117.3, 113.0, 101.4, 75.3, 31.4, 26.5, 17.1. MS (70 eV, m/z) (%):
[M+1] 355 (10), 354 (39), 299 (26), 298 (100), 162 (6), 130 (56),
115 (7), 114 (7), 102 (22), 41 (5).
4.6. 5,5-Dimethyl-2-phenyl-4,5-dihydro-3H-furo[30,20:3,4]
naphtho[1,2-d]imidazole (25)
Using nor-b-lapachone (228 mg, 1 mmol) and benzaldehyde
(265 mg, 2.5 mmol), 25 was obtained as a yellow solid (157 mg,
0.5 mmol, 50% yield, mp 265–266 C).
IR mmax(cm1, KBr): 3100 (Ar-CH), 1606 (C@N), 1110 (C–O–C).
1H NMR (200 MHz, DMSO-d6) d: 8.47 (1H, d, J = 8 Hz), 8.2 (2H,
m), 7.88 (1H, d, J = 8 Hz), 7.66–7.13 (5H, m), 2.5 (s, 2H); 1.5 (s,
6H). MS (70 eV, m/z) (%): 314 (100); 299 (75); 272 (8); 245 (3);
210 (4); 196 (11); 169 (8); 149 (11); 115 (8); 77 (6); 57 (8).
4.7. 5,5-Dimethyl-2-(p-tolyl)-4,5-dihydro-3H-furo[30,20:3,4]
naphtho[1,2-d]imidazole (26)
Using nor-b-lapachone (456 mg, 2 mmol) and 4-metyl benzal-
dehyde (540 mg, 4.5 mmol), 26 was obtained as a white solid
(98 mg, 0.30 mmol, 15% yield, mp 275–278 C).
IR mmax(cm1, KBr): 3140 (Ar-CH), 1606 (C@N), 1123 (C–O–C).
1H NMR (400 MHz, DMSO-d6) d: 8.48 (1H, d, J = 8.0 Hz), 8.14–
8.06 (2H, m), 7.89 (1H, d, J = 8.0 Hz), 7.57 (1H, t, J = 7.5 Hz), 7.44
(1H, t, J = 7.5 Hz), 7.38–7.34 (2H, m), 3.37 (2H, s), 2.39 (3H, s),
1.58 (6H, s). MS (70 eV, m/z) (%): 328 (64), 313 (55), 299 (5), 285
(7), 196 (6), 167 (8), 140 (14), 130 (9), 115 (22), 102 (12), 91
(27), 77 (14), 65 (15), 41 (100).
4.8. 5,5-Dimethyl-2-(4-nitrophenyl)-4,5-dihydrofuro
[30,20:3,4]naphtho[1,2-d]oxazole (27)
Using nor-b-lapachone (456 mg, 2 mmol) and p-NO2 benzalde-
hyde (679.5 mg, 4.5 mmol), 27 was obtained as a red solid
(410 mg, 1.14 mmol, 57% yield, mp 224–226 C).
IR mmax(cm1, KBr): 1600 (C@N),1553, 1316 (NO2), 1256 (C–O–
C), 1105 (C–O–C). 1H NMR (400 MHz, CDCl3) d: 8.52 (1H, d,
J = 8.2 Hz), 8.45–8.34 (4H, m), 8.08 (1H, d, J = 8.2 Hz), 7.69–7.62
(1H, m), 7.57–7.50 (1H, m), 3.43 (2H, s), 1.67 (6H, s). MS (70 eV,
m/z) (%): 360 (75), 330 (8), 318 (11), 197 (11), 169 (20), 47 (100).
4.9. 5,5-Dimethyl-2-(p-tolyl)-4,5-dihydrofuro[30,20:3,4]
naphtho[1,2-d]oxazole (28)
Using b-nor-lapachone (456 mg, 2 mmol) and p-methyl benzal-
dehyde (540 mg, 4.5 mmol), 28 was obtained as a white solid
(86 mg, 0.26 mmol, 13% yield, mp 198–200 C).
IR mmax(cm1, KBr): 1612 (C@N), 1258 (C–O–C), 1065 (C–O–C).
1H NMR (400 MHz, CDCl3) d: 8.44 (1H, d, J = 8.2 Hz), 8.08 (2H, d,
J = 7.9 Hz), 7.97 (1H, d, J = 8.2 Hz), 7.56–7.48 (1H, m), 7.44–7.36
(1H, m), 7.24 (2H, d, J = 7.9 Hz), 3.33 (2H, s), 2.35 (3H, s), 1.56
(6H, s). MS (70 eV, m/z) (%): 329 (100), 314 (8), 300 (2), 287 (16),
197 (15), 169 (16), 141 (10), 139 (7), 119 (33), 91 (23).4.10. 5-Methyl-2-(4-nitrophenyl)-4,5-dihydrofuro[30,20:3,4]
naphtho[1,2-d]oxazole (31)
Using compound 30 (428 mg, 2 mmol) and p-NO2 benzaldehyde
(679.5 mg, 4.5 mmol), 31 was obtained as a red solid (138 mg,
0.40 mmol, 20% yield, mp 234–237 C).
IR mmax(cm1, KBr): 1600 (C@N), 1258 (C–O–C), 1130 (C–O–C).
1H NMR (400 MHz, CDCl3) d: 8.52 (1H, d, J = 8.2 Hz), 8.44–8.32
(4H, m), 8.07 (1H, d, J = 8.2 Hz), 7.68–7.64 (1H, m), 7.56–7.52
(1H, m), 5.41–5.26 (1H, m), 3.75 (1H, dd, J = 15.2, 9.2 Hz), 3.23
(1H, dd, J = 15.2, 7.4 Hz), 1.65 (3H, s). MS (70 eV, m/z) (%): 346
(92), 316 (19), 300 (20), 228 (7), 155 (24), 141 (34), 127 (23),
115 (61), 102 (31), 88 (29), 76 (100), 63 (31), 43 (77).
4.11. Minimum inhibitory concentration determination
The experiment was performed using Mycobacterium tuberculo-
sis H37Rv (ATCC27294), a pan-susceptible strain, RIFr with a His-
526?Tir mutation in the rpoB gene and INHR with a Ser-315?Tir
mutation in the katG gene. The strains were maintained in Oga-
wa-Kudoh media for 14 days at 37 C.
The determination of antimycobacterial activity was performed
by REMA (Resazurin Microtitre Assay), as previously described.23 In
brief, the bacterial suspensions were homogenized by vortex
agitation, and the turbidity was adjusted in agreement with tube
one of the scale 1.0 of McFarland (3.2  106 cfu/mL). The inoculum
was prepared by diluting the bacterial suspension 1:20 in Middle-
brook 7H9 OADCmedia (4.7 g Middlebrook 7H9 base; Difco, Becton
Dickinson). The 7H9 medium consisted of 0.5 g of ammonium sul-
fate, 0.5 g of L-glutamic acid, 0.1 g of sodium citrate, 0.001 g of pyr-
idoxine, 0.0005 g of biotin, 2.5 g of disodium phosphate, 1.0 g of
monopotassium phosphate; 0.04 g ferric ammonium citrate,
0.05 g of magnesium sulfate, 0.0005 g of calcium chloride, 0.001 g
of Zinc sulfate, 0.001 g of copper sulfate, 2 mL of glycerol, 900 mL
of H2O, and 10% OADC (oleic acid, albumin, dextrose, catalase).
The assay was performed in 96-well microplates, with a concentra-
tion of 100 lg/mL in the ﬁrst well and up to 0.19 lg/mL in the last
well. The microplate was incubated at 37 C for 7 days. After this,
30 lL of resazurin was added to each well, and the plate was
incubated for 2 days at 37 C. The reading was recorded from the
oxi-reduction of the resazurin, noting the change of color when
cellular growth was taking place.
4.12. Inhibition of PBMC proliferation
To investigate the selectivity of compounds toward a normal
proliferating cell, the Alamar blue assay was performed with
peripheral blood mononuclear cells (PBMC) after 72 h of drug
exposure. After 24 h, compounds (0.048 to 25 lg/mL) dissolved
in DMSO (0.1%) were added to each well and incubated for 72 h.
Twenty-four h before the end of the incubation, 10 lL of stock
solution (0.312 mg/mL) of the Alamar Blue (Resazurin, Sigma–Al-
drich Co) was added to each well. The absorbance was measured
using a multiplate reader (DTX 880 Multimode Detector, Beckman
Coulter) and the drug effect was quantiﬁed as the percentage of
control absorbance at 570 nm and 595 nm. The absorbance of Ala-
mar Blue in culture medium is measured at a higher wavelength
and a lower wavelength. The absorbance of the medium is also
measured at the higher and lower wavelengths. The absorbance
of the medium alone is subtracted from the absorbance of medium
plus Alamar Blue at the higher wavelength. This value is called
AOHW. The absorbance of the medium alone is subtracted from
the absorbance of medium plus Alamar Blue at the lower wave-
length. This value is called AOLW. A correction factor, R0, can be
calculated from AOHW and AOLW, where R0 = AOLW/AOHW. The
6488 K. C. G. Moura et al. / Bioorg. Med. Chem. 20 (2012) 6482–6488percent Alamar Blue reduced is then expressed as follows:% redu-
ced = ALW—(AHW  R0)  100.
4.13. X-ray crystallographic analysis
Data for each compound were collected at room temperature on
an Enraf Nonius FR590 charge-coupled device (CCD) area-detector
diffractometer (Mo Ka graphite-monochromated radiation,
k = 0.71073 Å) controlled by the COLLECT software package.24
Images were processed using the Denzo and Scalepack software
packages.25 The structures were solved using direct methods with
SHELXS-9726 and reﬁned by full-matrix least squares on F2 using
SHELXL-97.26 All non-hydrogen atoms were successfully reﬁned
using anisotropic displacement parameters.
Crystallographic data (excluding structure factors) for the struc-
tures reported in this paperhavebeendepositedwith theCambridge
Crystallographic Data Centre as supplementary publication No.
CCDC 814214, 814215, 882547, 882549 and 882552. Copies of the
data can be obtained free of charge on application to CCDC, 12Union
Road, Cambridge CB2 2EZ, UK (Fax: (+44) 1223 336033; e-mail:
deposit@ccdc.cam.ac.uk).
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